José Valdez Madruga

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2007 · 515 citations

Treatment-experienced Hiv-1-infected Patients, Treatment And Prevention, Human Retrovirus +11

Mpox in people with advanced HIV infection: a global case series

Andrea Alemany, Michael Marks, Jezer I Lezama Mora et al. · The Lancet · 2023 · 452 citations · Full text

Advanced Hiv Infection, Sexual Health, Treatment And Prevention +8

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

José Valdez Madruga, Daniel Berger, Marilyn McMurchie et al. · The Lancet · 2007 · 330 citations

Treatment And Prevention, Antiviral Drug Development, Antiviral Therapy +5

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu et al. · New England Journal of Medicine · 2024 · 169 citations

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Beatriz Grinsztejn, Nathalie De Castro, Vincent Arnold et al. · The Lancet Infectious Diseases · 2014 · 98 citations

Pulmonary Tuberculosis, Treatment And Prevention, Randomised Trial +9